• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS FT4 IV; FREE THYROXINE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS FT4 IV; FREE THYROXINE Back to Search Results
Catalog Number 09043284190
Device Problem High Test Results (2457)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 02/01/2024
Event Type  malfunction  
Event Description
The initial reporter complained of discrepant results for 1 patient sample tested for elecsys ft3 iii (ft3 iii), and elecsys ft4 iv (ft4 iv) on a cobas e 801 analytical unit compared to a competitor method.This medwatch will cover ft4 iv.Refer to medwatch with a1 patient identifier (b)(6) for information on the ft3 iii results.On (b)(6) 2024 the ft3 iii result from the e801 analyzer was 22.1 pg/ml.On (b)(6) 2024 the ft4 iv result from the e801 analyzer was 6.68 ng/dl.The patient was moved to a different hospital.On (b)(6) 2024 the thyroid results from the other hospital were "normal." due to the "normal" results from the other hospital, the customer sent the patient sample to an external laboratory for testing by a competitor method.On (b)(6) 2024 the ft3 result from the competitor method was 3.7 pg/ml.On (b)(6) 2024 the ft4 result from the competitor method was 1.5 ng/dl.
 
Manufacturer Narrative
The e801 analyzer serial number was (b)(6).The competitor method was tosoa aia-600.The sample was requested for investigation.
 
Manufacturer Narrative
A new sample was obtained from the patient on (b)(6) 2024.The results were similar to the initial results from (b)(6) 2024.The sample was submitted for investigation and discrepant results were identified for ft3 iii and ft4 iv between the customer's e801 analyzer, an e801 analyzer used at the investigation site, an e411 analyzer used at the investigation site, and the abbott architect method.See the attached data for the patient results.The e801 analyzer used at the investigation site was (b)(6).The e411 analyzer used at the investigation site was (b)(6).The ft3 iii v2 reagent lot number used with the e411 analyzer was 686656 with an expiration date of 31-apr-2024.The ft3 iii v2 reagent lot number used with the e801 analyzer was 737314 with an expiration date of 30-nov-2024.The ft4 iv reagent lot number used at the investigation site was 724974 with an expiration date of 31-may-2024.The investigation is ongoing.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS FT4 IV
Type of Device
FREE THYROXINE
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhofer strasse 116
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
amy nelson
9115 hague road
indianapolis, IN 46250
MDR Report Key18817621
MDR Text Key336737445
Report Number1823260-2024-00615
Device Sequence Number1
Product Code CEC
Combination Product (y/n)Y
Reporter Country CodeJA
PMA/PMN Number
K220456
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 03/27/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/01/2024
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number09043284190
Device Lot Number724974
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/06/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
BISOPROLOL FUMARATE; EMPAGLIFLOZIN; RIVAROXABAN
-
-